重新评估肝移植治疗混合型肝细胞-胆管癌
该研究基于前瞻性数据库分析2010至2024年间79例肝移植和32例肝切除的混合型肝细胞-胆管癌患者,发现肝移植的5年总生存率和无复发生存率均优于肝切除,且在UCSF标准内获益持续;肝移植后生存与肝细胞癌相当,大血管侵犯和低分化是复发独立预测因素。
要点
- 肝移植治疗cHCC-CCA的5年OS和RFS优于肝切除。
- 符合UCSF标准的cHCC-CCA肝移植后生存与HCC相当。
- 大血管侵犯和低分化是肝移植后复发的独立预测因素。
核心结论
- 经过严格选择的UCSF标准内cHCC-CCA患者,肝移植可获得与HCC相当的结局。
- 大血管侵犯和肿瘤低分化是复发的主要预测因素,可能有助于筛选肝移植候选者。
研究设计与样本
- 前瞻性数据库研究,纳入2010至2024年间接受肝移植(79例,经 explant 诊断)或肝切除(32例)的cHCC-CCA患者。
- 分析生存结局、复发模式及复发危险因素,并将cHCC-CCA肝移植结局与HCC进行比较。
主要发现
- 肝移植对比肝切除:5年OS为89.9% vs. 65.6%(P=0.007),5年RFS为84.8% vs. 53.1%(P=0.001)。
- UCSF标准内肿瘤:肝移植对比肝切除的OS为88.7% vs. 65.6%(log rank P=0.014),RFS为89.8% vs. 51.6%(P<0.001)。
- 肝移植受者中,cHCC-CCA与HCC的OS相当(89.9% vs. 86%,P=0.721)。
- 肝移植队列中,大血管侵犯(HR 25.01,P=0.003)和肿瘤低分化(HR 7.29,P=0.004)独立预测复发。
关键数值与推荐
- UCSF标准内cHCC-CCA肝移植后5年OS为88.7%,RFS为89.8%。
- 大血管侵犯复发HR为25.01(P=0.003),肿瘤低分化复发HR为7.29(P=0.004)。
临床怎么用
- 对于严格选择的UCSF标准内cHCC-CCA患者,可考虑肝移植而非肝切除,以改善长期生存。
- 术前评估应关注大血管侵犯和肿瘤分化程度,作为肝移植候选筛选的重要参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ann Surg . 2026 Oct 30. doi: 10.1097/SLA.0000000000007156. Online ahead of print. ABSTRACT OBJECTIVE: To determine whether liver transplantation (LT) confers durable oncologic benefit in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and to identify predictors of recurrence that may guide transplant candidacy. BACKGROUND: cHCC-CCA is a rare primary liver malignancy with aggressive biological behavior. LT has traditionally been contraindicated due to concerns regarding recurrence. We evaluated long-term outcomes of LT versus liver resection (LR) and compared LT outcomes for cHCC-CCA with those for hepatocellular carcinoma (HCC). METHODS: Patients with cHCC-CCA who underwent LT or LR between 2010 and 2024 were identified from a prospective database. Survival outcomes, recurrence patterns, and risk factors for recurrence were analyzed. Outcomes of LT for cHCC-CCA were additionally compared with HCC. RESULTS: A total of 79 patients underwent LT (diagnosed on explant) and 32 underwent LR for cHCC-CCA. 5-year overall survival (OS) and recurrence-free survival (RFS) were superior following LT compared with LR (OS: 89.9% vs. 65.6%, P=0.007; RFS: 84.8% vs. 53.1%, P=0.001). This benefit was maintained for tumors within UCSF criteria [overall survival (88.7% LT vs. 65.6% LR, log rank P 0.014) and RFS (89.8% LT vs. 51.6% LR, P<0.001)]. Among LT recipients, OS for cHCC-CCA was comparable to HCC (89.9% vs. 86%, P=0.721). Within the LT cohort, macrovascular invasion (HR 25.01, P=0.003) and poor tumor differentiation (HR 7.29, P=0.004) independently predicted recurrence. CONCLUSION: In carefully selected patients, cHCC-CCA within UCSF criteria can achieve transplant outcomes comparable to HCC. Macrovascular invasion and poor tumor differentiation are major predictors of recurrence and may inform candidate selection for LT. PMID: 42960453 | DOI: 10.1097/SLA.0000000000007156
引用
- PubMed · Ann Surg:Reappraising Liver Transplantation for Combined Hepatocellular-cholangiocarcinoma
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。